JP2024525998A - 脳梗塞治療用医薬組成物 - Google Patents

脳梗塞治療用医薬組成物 Download PDF

Info

Publication number
JP2024525998A
JP2024525998A JP2023570055A JP2023570055A JP2024525998A JP 2024525998 A JP2024525998 A JP 2024525998A JP 2023570055 A JP2023570055 A JP 2023570055A JP 2023570055 A JP2023570055 A JP 2023570055A JP 2024525998 A JP2024525998 A JP 2024525998A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cerebral infarction
composition according
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525998A5 (enExample
Inventor
ニシムラ、ナオコ
ハスミ、ケイジ
ホンダ、カズオ
Original Assignee
ジーシン ファーマシューティカルズ ホンコン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーシン ファーマシューティカルズ ホンコン リミテッド filed Critical ジーシン ファーマシューティカルズ ホンコン リミテッド
Publication of JP2024525998A publication Critical patent/JP2024525998A/ja
Publication of JP2024525998A5 publication Critical patent/JP2024525998A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2023570055A 2021-05-10 2022-05-10 脳梗塞治療用医薬組成物 Pending JP2024525998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079820 2021-05-10
JP2021079820 2021-05-10
PCT/US2022/028488 WO2022240810A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Publications (2)

Publication Number Publication Date
JP2024525998A true JP2024525998A (ja) 2024-07-16
JP2024525998A5 JP2024525998A5 (enExample) 2025-04-30

Family

ID=82214306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570055A Pending JP2024525998A (ja) 2021-05-10 2022-05-10 脳梗塞治療用医薬組成物

Country Status (9)

Country Link
US (1) US20240238248A1 (enExample)
EP (1) EP4337193A1 (enExample)
JP (1) JP2024525998A (enExample)
KR (1) KR20240005749A (enExample)
CN (1) CN117295497A (enExample)
AU (1) AU2022275263A1 (enExample)
BR (1) BR112023023534A2 (enExample)
CA (1) CA3216137A1 (enExample)
WO (1) WO2022240810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
WO2011004620A1 (ja) * 2009-07-06 2011-01-13 国立大学法人東京農工大学 細胞保護剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Ｓｍｔｐ一群又はｓｍｔｐ－７の製造中間体及びその化学的製造方法
CN121064221A (zh) * 2021-02-10 2025-12-05 福建盛迪医药有限公司 一种smtp-7衍生物及其用途
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
WO2011004620A1 (ja) * 2009-07-06 2011-01-13 国立大学法人東京農工大学 細胞保護剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
「新医薬品の臨床評価に関する一般指針について」（薬新薬第四三号）各都道府県衛生主管部局長あて厚生省薬, JPN6021034322, 1992, pages 1 - 12, ISSN: 0005856176 *
JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 34, no. 2, JPN6026018460, 2013, pages 235 - 241, ISSN: 0005856175 *
NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 382, no. 3, JPN6026018458, 2010, pages 245 - 253, ISSN: 0005856173 *
PHARMACOLOGY RESEARCH & PERSPECTIVES, vol. 6, no. 6, JPN6026018459, 2018, pages 00448, ISSN: 0005856174 *

Also Published As

Publication number Publication date
AU2022275263A1 (en) 2023-11-09
EP4337193A1 (en) 2024-03-20
BR112023023534A2 (pt) 2024-01-30
US20240238248A1 (en) 2024-07-18
KR20240005749A (ko) 2024-01-12
CN117295497A (zh) 2023-12-26
CA3216137A1 (en) 2022-11-17
WO2022240810A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
AU2017202726B2 (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
JP7042531B2 (ja) デオキシコール酸を含む医薬組成物
JP7082115B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
EP3181121B1 (en) Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
JP2019526542A (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
US8329693B2 (en) Method for the prevention of thromboembolic disorders
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
JP2024525239A (ja) 化合物ｓｍｔｐ－７を含有する医薬組成物
US20050255096A1 (en) Combination treatment for acute myocardial infarction
Howard The management of ischaemic stroke
US20070123567A1 (en) Prophylactic pretreatment with antioxidants
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
CN120603579A (zh) 新型溶液
Kurosawa et al. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and Baloxavir Marboxil in a patient on implantable ventricular assist device
EP4176873A1 (en) Urinary symptom therapeutic agent
Bonitsis et al. Current concepts in the treatment of Adamantiades-Behçet's disease
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
JP2023543132A (ja) シクロデキストリンによるコレステロール結晶塞栓症の予防方法
WO2021136549A1 (zh) 马来酸桂哌齐特用于制备防治脑卒中的药物中的应用
Bonitsis et al. Current concepts in the treatment of Adamantadies-Behcet
WO2007013842A1 (en) Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
JP2003073272A (ja) 脳梗塞進展防止剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260729